Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Omnia Biologics, Inc.
Omnia Biologics and Sumagen Announce Successful Manufacture of HIV/AIDS Vaccine Phase I Material
February 18th, 2009
Omnia Biologics, Inc. (Rockville, MD) and Sumagen Co., Ltd. (London, ON) today jointly announced the successful completion of cGMP manufacture of Sumagen’s HIV/AIDS vaccine for a Phase I clinical trial. Safe, effective vaccines for HIV prophylaxis and therapy remain a vital and elusive goal in the fight against infectious disease. The need for new clinical candidates for HIV/AIDS is pressing since recent failures of other late stage products. “The team at Omnia is very pleased to have assisted Sumagen in this important effort addressing the new priorities of the path forward in the wake of the STEP study,” commented Dr. Dale VanderPutten, CEO of Omnia Biologics....
Source: Vaccine Weekly (2009-02-18)
|
